Moderna is no longer just a COVID-19 vaccine company. A growing pipeline could fuel long-term revenue growth.

Moderna (MRNA) closed at $81.76 in the latest trading session, marking a +2.51% move from the prior day.

Each of these biotech players has reached an important turning point. Recent drug approvals could supercharge the performance of one in particular.

Tom Yeung here with your Sunday Digest . In the days following its IPO, Space Exploration Technologies Corp. ( SPCX ) surged 25%, rewarding early investors and turning its owner, Elon Musk, into a trillionaire.

An FDA advisory panel voted 9-0 that Moderna's mRNA flu vaccine's benefits outweigh its risks. A final approval decision is expected by Aug. 5.

Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.

Moderna is evolving from a COVID-19 vaccine specialist into a multi-product firm with major oncology and rare disease partnerships. Recursion Pharmaceuticals is leveraging artificial intelligence and massive biological datasets to accelerate drug discovery via high-tech collaborations.

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.

Moderna Inc. (MRNA) shares rose 9.2% on Thursday, making the biotechnology company among the top performers in the S&P 500 as investors responded positively to new pipeline updates, encouraging influenza vaccine data, and favorable analyst commentary. The stock extended its recent rally after climbing to a new annual high on Wednesday.

At that time, Moderna revealed its strategy for using mRNA to combat cancer and rare diseases. It's a move beyond vaccines, and investors seem to like it.